A prospective comparison between magnetic resonance imaging, meta-iodobenzylguanidine scintigraphy and marrow histology/cytology in neuroblastoma

Corbett, Robin; Olliff, J.; Fairley, N. Hamilton; Moyes, Judy S.; Husband, Janet E.; Pinkerton, Ross; Carter, Richard; Treleaven, J; McElwain, T. J.; Meller, S

doi:10.1016/0277-5379(91)90415-a

Cited by 34 publications

(19 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A high rate of false-negative bone marrow metastases, which can be detected on MRI, on MIBG scintigraphy and poor specificity of MRI was reported by these authors [14,30,31]. These findings are consistent with our study findings-a relatively low sensitivity on MIBG scintigraphy and low specificity on MRI in detecting not only bone marrow metastases but also all neuroblastoma lesions.…”

Section: Discussionsupporting

confidence: 94%

Integrated Imaging Using MRI and ¹²³| Metaiodobenzylguanidine Scintigraphy to Improve Sensitivity and Specificity in the Diagnosis of Pediatric Neuroblastoma

Pfluger

Schmied

Porn

et al. 2003

American Journal of Roentgenology

104

View full text Add to dashboard Cite

show abstract

Section: Discussionsupporting

confidence: 94%

Integrated Imaging Using MRI and ¹²³| Metaiodobenzylguanidine Scintigraphy to Improve Sensitivity and Specificity in the Diagnosis of Pediatric Neuroblastoma

Pfluger

Schmied

Porn

et al. 2003

American Journal of Roentgenology

104

View full text Add to dashboard Cite

show abstract

“…Should this be the case, patients who show negative uptake after induction may be a mixed group between very good and extremely poor responders. Whether magnetic resonance imaging might be more specific remains speculative [16]. The other bias of these studies is the dose of MIBG used and the duration and timing of the procedure.…”

Section: Discussionmentioning

confidence: 97%

Metaiodobenzylguanidine assessment of metastatic neuroblastoma: Observer dependency and chemosensitivity evaluation

Frappaz

Bonneu

Chauvot

et al. 2000

Med. Pediatr. Oncol.

View full text Add to dashboard Cite

“…For metastases this is of great importance, because the presence of metastases classifies the patient as stage 4 or 4S and this has severe consequences for the prognosis and treatment. A possible candidate as add-on test might be 18 F-FDG-PET(-CT) or MRI (Corbett 1991b; Siegel 2013). In this Cochrane DTA review we reviewed the diagnostic accuracy of 18 F-FDG-PET(-CT).…”

Section: Discussionmentioning

confidence: 99%

123I-MIBG scintigraphy and 18F-FDG-PET imaging for diagnosing neuroblastoma

Bleeker¹,

Tytgat

Adam

et al. 2015

Cochrane Database of Systematic Reviews

View full text Add to dashboard Cite

Background Neuroblastoma is an embryonic tumour of childhood that originates in the neural crest. It is the second most common extracranial malignant solid tumour of childhood. Neuroblastoma cells have the unique capacity to accumulate Iodine‐123‐metaiodobenzylguanidine (¹²³I‐MIBG), which can be used for imaging the tumour. Moreover, ¹²³I‐MIBG scintigraphy is not only important for the diagnosis of neuroblastoma, but also for staging and localization of skeletal lesions. If these are present, MIBG follow‐up scans are used to assess the patient's response to therapy. However, the sensitivity and specificity of ¹²³I‐MIBG scintigraphy to detect neuroblastoma varies according to the literature. Prognosis, treatment and response to therapy of patients with neuroblastoma are currently based on extension scoring of ¹²³I‐MIBG scans. Due to its clinical use and importance, it is necessary to determine the exact diagnostic accuracy of ¹²³I‐MIBG scintigraphy. In case the tumour is not MIBG avid, fluorine‐18‐fluorodeoxy‐glucose ( 18 F‐FDG) positron emission tomography (PET) is often used and the diagnostic accuracy of this test should also be assessed. Objectives Primary objectives: 1.1 To determine the diagnostic accuracy of ¹²³I‐MIBG (single photon emission computed tomography (SPECT), with or without computed tomography (CT)) scintigraphy for detecting a neuroblastoma and its metastases at first diagnosis or at recurrence in children from 0 to 18 years old. 1.2 To determine the diagnostic accuracy of negative ¹²³I‐MIBG scintigraphy in combination with 18 F‐FDG‐PET(‐CT) imaging for detecting a neuroblastoma and its metastases at first diagnosis or at recurrence in children from 0 to 18 years old, i.e. an add‐on test. Secondary objectives: 2.1 To determine the diagnostic accuracy of 18 F‐FDG‐PET(‐CT) imaging for detecting a neuroblastoma and its metastases at first diagnosis or at recurrence in children from 0 to 18 years old. 2.2 To compare the diagnostic accuracy of ¹²³I‐MIBG (SPECT‐CT) and 18 F‐FDG‐PET(‐CT) imaging for detecting a neuroblastoma and its metastases at first diagnosis or at recurrence in children from 0 to 18 years old. This was performed within and between included studies. ¹²³I‐MIBG (SPECT‐CT) scintigraphy was the comparator test in this case. Search methods We searched the databases of MEDLINE/PubMed (1945 to 11 September 2012) and EMBASE/Ovid (1980 to 11 September 2012) for potentially relevant articles. Also we checked the reference lists of relevant articles and review articles, scanned conference proceedings and searched for unpublished studies by contacting researchers involved in this area. Selection criteria We included studies of a cross‐sectional design or cases series of prove...

show abstract

A prospective comparison between magnetic resonance imaging, meta-iodobenzylguanidine scintigraphy and marrow histology/cytology in neuroblastoma

Cited by 34 publications

References 23 publications

Integrated Imaging Using MRI and ¹²³| Metaiodobenzylguanidine Scintigraphy to Improve Sensitivity and Specificity in the Diagnosis of Pediatric Neuroblastoma

Integrated Imaging Using MRI and ¹²³| Metaiodobenzylguanidine Scintigraphy to Improve Sensitivity and Specificity in the Diagnosis of Pediatric Neuroblastoma

Metaiodobenzylguanidine assessment of metastatic neuroblastoma: Observer dependency and chemosensitivity evaluation

123I-MIBG scintigraphy and 18F-FDG-PET imaging for diagnosing neuroblastoma

Contact Info

Product

Resources

About

A prospective comparison between magnetic resonance imaging, meta-iodobenzylguanidine scintigraphy and marrow histology/cytology in neuroblastoma

Cited by 34 publications

References 23 publications

Integrated Imaging Using MRI and 123| Metaiodobenzylguanidine Scintigraphy to Improve Sensitivity and Specificity in the Diagnosis of Pediatric Neuroblastoma

Integrated Imaging Using MRI and 123| Metaiodobenzylguanidine Scintigraphy to Improve Sensitivity and Specificity in the Diagnosis of Pediatric Neuroblastoma

Metaiodobenzylguanidine assessment of metastatic neuroblastoma: Observer dependency and chemosensitivity evaluation

123I-MIBG scintigraphy and 18F-FDG-PET imaging for diagnosing neuroblastoma

Contact Info

Product

Resources

About

Integrated Imaging Using MRI and ¹²³| Metaiodobenzylguanidine Scintigraphy to Improve Sensitivity and Specificity in the Diagnosis of Pediatric Neuroblastoma

Integrated Imaging Using MRI and ¹²³| Metaiodobenzylguanidine Scintigraphy to Improve Sensitivity and Specificity in the Diagnosis of Pediatric Neuroblastoma